Success Story of Extracorporeal Shock Wave Therapy (ESWT)
Successful for over 40 years in urology for the disintegration of kidney stones, with high efficiency and hardly any side effects worth mentioning.
How does the shock wave work?
Without causing mechanical damage, shockwaves trigger a biological response in the treated tissue through their compressive, tensile and shear forces (mechanotransduction). Genes are activated in the cell nucleus starting to produce proteins (including growth factors) responsible for the healing process. This also causes increased ingrowth of newly formed blood vessels, which improves local metabolism. The additional modulation of the inflammation necessary for healing enables regeneration of pathological tissue.
Recent studies prove.
Shockwaves also trigger the production of messenger substances to the cell nucleus, which mobilize the body's own stem cells from the bone marrow, stimulating them to migrate to the treated tissue, settle there and develop into the required tissue (e.g. heart muscle cells). Instead of conventional stem cell transplantation shockwaves make it possible to initiate the body's own regeneration without risk of complications.
Therapy for a wide variety of tissues.
Since the underlying pathology can be treated with these methods, shockwave therapy is being used in more and more medical disciplines.
This creates a tool that opens up completely new possibilities in tissue regeneration without triggering significant side effects. Since conventional medicine has not been able to offer any significant therapeutic options to date, the present results of shockwave therapy are of particular importance and are therefore applied in the following areas. It can be assumed that shockwave therapy can be used in practically all medical specialties.
Spinal cord injury/cross-sectional lesion.
What was long considered unthinkable is now one of the major hopes for causal therapy: shockwave has also made great progress in the treatment of paraplegia. Since November 2020, the first patients have been included in an Austria-wide study. Due to the COVID pandemic, the initiation of the individual study centers has been somewhat delayed, but so far eight patients have already been enrolled in the study. In addition, the Unfallkrankenhaus Berlin, one of the most important centers for spinal cord injury in Germany, will participate in the study.
Dr. Wolfgang Schaden, adj. Prof., President of ISMST, Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Deputy Medical Director of AUVA, Austria
Regeneration of heart muscle after myocardial infarction has long remained a dream of modern medicine. Despite extensive efforts to develop stem cell and gene therapies, none of these methods could be brought into clinical routine. Cardiac shockwave therapy brings a scientific breakthrough: Cardiac function is improved, and impressive results show the increase of patients' quality of life. Shockwave therapy in cardiac surgery has a favorable side effect profile and is on the verge of bringing cardiac regeneration into daily clinical practice.
PD Dr. Johannes Holfeld, University Department of Cardiac Surgery, Innsbruck Medical University, Austria.
Low-energy shockwave therapy has been a fabulous addition to sexual medicine armamentarium for men and women with various forms of sexual dysfunction, e.g. erectile dysfunction, premature ejaculation, persistent genital arousal disorder PGAD/genito-pelvic dysesthesia GPD. Many patients (and their partners) describe these comfortable and quick shockwave treatments as life changing.
Prof. Dr. Irwin Goldstein, Alvarado Hospital, San Diego, CA, USA
Aesthetic-, hand-, burn- and reconstructive surgery.
Shockwave medicine can support these four pillars of surgery noninvasively. Two significant examples: In aesthetic surgery with significant improvement in cellulite with shockwave therapy after six to eight sessions, lasting for a period of about one year. In burns, shockwave therapy can accelerate epithelialization (healing) of superficial burn injuries clinically relevant by three days, with a significant reduction in infections and hospitalization.
Prof. Dr. Karsten Knobloch, SportPraxis Prof. Knobloch, Hanover, Secretary General of the German Shockwave Society DIGEST.
After more than 30 years of experience, shock wave treatment is now a standard in sports medicine and rehabilitation facilities worldwide.
Shockwaves used in a similar way as for diabetic foot ulcers have also led to the healing of wounds in leprosy patients and significantly improved the quality of life of these patients. This work, carried out in Agua de Dios, Colombia, by the Bosque University group in Bogot, is now being used in several medical centers around the world with very positive results.
Prof. Dr. Carlos Leal, Bosque University, Fenway Medical, Bogot, Colombia.
Chronic wounds are challenging for patients concerned and practitioners and will have an increasing impact on health care systems. Treatment with shockwaves has a positive conditioning influence on the wounds and in a high proportion for healing, independent of otherwise aggravating factors (e.g. diabetes mellitus, immunosuppression, cortisone therapy, and other exacerbating factors).
With an average treatment frequency of one treatment every second week, in addition to the established wound therapy, healing was observed in more than 70% of the cases of ulcers and other wound healing disorders.The therapy is free of side effects and helps to reduce the burden of the health care system due to the enormous savings potential.
Rainer Mittermayr, MD, MBA, assoc. Prof., Treasurer of the ISMST and Conference Secretary, Senior Surgeon Orthopedic and Traumatology, AUVA (Austrian Workers Compensation Board, Vienna, Austria)
See the article here:
- Wealth of Newer Treatment Options Span the Scope of Multiple Myeloma and Amyloidosis - OncLive - January 16th, 2022
- Trial of Cell Therapy to Raise HbF Levels Showing Potential, But... - Sickle Cell Anemia News - January 16th, 2022
- What it's like in academic family medicine: Shadowing Dr. Rouhbakhsh - American Medical Association - January 16th, 2022
- The Fusion of mRNA and Immunotherapy - NEO.LIFE - January 16th, 2022
- Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference - The Bakersfield Californian - January 11th, 2022
- BioCardia Announces Participation at the Upcoming Digital Medicine & Medtech Showcase and the H.C. Wainwright BioConnect Virtual Conference -... - January 11th, 2022
- Equillium Announces Multiple Abstracts Accepted for Presentation at the Transplantation & Cellular Meetings of ASTCT and CIBMTR - Yahoo Finance - January 11th, 2022
- Houston TX Diabetes Stem Cell Treatment Regenerative Medicine Therapy Launch - Digital Journal - January 9th, 2022
- Stem Cell Rejuvenation Center - January 9th, 2022
- Cartesian Aims to Propel RNA Cell Therapy with Combinations - BioSpace - January 9th, 2022
- Orthopedic Biomaterials Product Market: Hip implant product segment is anticipated to carry major share of the market - BioSpace - January 9th, 2022
- Gamida Cell Announces Data to be Presented at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings - Business Wire - January 9th, 2022
- Jakubowiak Talks Daratumumab Quadruplet Therapy and the GRIFFIN Study at 2021 ASH - Cancer Network - January 9th, 2022
- Part 1: Benefit Shown With Transplant and Combination Therapy in Multiple Myeloma - Targeted Oncology - January 9th, 2022
- Notch Therapeutics' Peter Zandstra Appointed to the Order of Canada - Yahoo Finance - January 7th, 2022
- FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVirs Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults... - January 7th, 2022
- BlueRock Therapeutics Announces Closeout of First Cohort in Phase 1 Trial in Patients with Advanced Parkinson's Disease - Yahoo Finance - January 7th, 2022
- Cellusion Raises 1.1B JPY to Advance Japan and Global Clinical Trials of CLS001 for Corneal Endothelial Cell Regenerative Therapy - Galveston County... - January 7th, 2022
- US FDA approves Phase 3 Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma - OncoZine - January 5th, 2022
- Alzheimer's Disease Expected to Triple by 2050 While the Development Process for Potential Drug Candidates Increases - PRNewswire - January 5th, 2022
- FDA Grants Regenerative Medicine Advanced Therapy Designation To AlloVir's Posoleucel For The Treatment Of Adenovirus Infections In Adults And... - January 5th, 2022
- Protecting people with cancer from COVID-19: - EurekAlert - January 5th, 2022
- Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual JP Morgan Healthcare Conference - TheNewswire.ca - January 5th, 2022
- Placental Stem Cell Therapy Market to Surpass US$ 4.4 Bn by 2030, Underpinned by Enormous R&D in Cellular Therapies and Regenerative Medicine, Finds... - January 3rd, 2022
- LifeBank Chain Announces Upcoming Gene and Cell Collaboration Platform With Disrupt Blockchain Technologies - AsiaOne - January 3rd, 2022
- Genomic variant may help predict which patients will experience chemotherapy-induced cardiotoxicity - News-Medical.Net - January 3rd, 2022
- lodie Yung plunges into the undocumented underworld in 'The Cleaning Lady' - Entertainment Weekly News - January 3rd, 2022
- Cellular Therapies Fill Unmet Needs in R/R Multiple Myeloma - Targeted Oncology - January 2nd, 2022
- Curi Bio Closes $10M Series A in Oversubscribed Round - BioSpace - December 31st, 2021
- Bring in the bulldozers: Cynatas CEO on how heavyweight FujiFilm will turbocharge its ... - Stockhead - December 31st, 2021
- Questions on Quadruplets and CAR T Set to be Answered As Myeloma Paradigm Parses Out the Clinical Value of MRD - OncLive - December 31st, 2021
- Stem Cell Therapy NYC, Regenerative Medicine Injections ... - December 29th, 2021
- James Shapiro, MD: Insulin Production In T1D Patients After Stem Cell Therapy - MD Magazine - December 29th, 2021
- Global Automated and Closed Cell Therapy Processing Systems - GlobeNewswire - December 29th, 2021
- Bill would pave way for organ donation - Stabroek News - December 29th, 2021
- Celularity Receives Fast Track Designation from US FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML - BioSpace - December 29th, 2021
- Valemetostat New Drug Application Submitted in Japan for Treatment of Patients with Adult T-Cell Leukemia/Lymphoma - Business Wire - December 29th, 2021
- 2021: The Year in Diabetes - Healthline - December 29th, 2021
- Covid infects kidneys and leads to scarring: Study - India New England - December 29th, 2021
- Fetal Gut May Have Insulin-Producing Cells That Shut Off at Birth - Medscape - December 29th, 2021
- Brem Looks at Multiple Treatments for Patients With DLBCL - Targeted Oncology - December 26th, 2021
- Delete Blood Cancer! How Content Creator Duo Abhi And Niyu Inspired Thousands To Give Someone Second... - The Logical Indian - December 25th, 2021
- The pathogenesis, natural history, and treatment of type 1 diabetes: time (thankfully) does not stand still - The Lancet - December 25th, 2021
- Ropinirole Proves Safe and Tolerable for Patients With ALS - Medscape - December 25th, 2021
- Major international research center may drive the development of future stem cell-based treatments - News-Medical.Net - December 19th, 2021
- Receiving CAR-T therapy sooner improves lymphoma survival, according to study published in New England Journal of Medicine - Newswise - December 19th, 2021
- Latest Cancer Research: CAR T to Liquid Biopsies - Healthline - December 19th, 2021
- Trials of stem cell therapy offer hope to childless women in Bangladesh - The Financial Express BD - December 19th, 2021
- UC San Diego Breaks Ground on Revitalization of Hillcrest Campus - UC San Diego Health - December 19th, 2021
- BioLineRx Provides Highlights from Oral Presentation Delivered at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition -... - December 19th, 2021
- CAR-T Cell Therapy Continues to Impress in Myeloma Treatment - Curetoday.com - December 17th, 2021
- CAR-T therapy trials show promise for earlier use in lymphoma - BioPharma Dive - December 17th, 2021
- Cedars-Sinai researchers discover growth hormone in the colon that influences aging process - News-Medical.Net - December 17th, 2021
- Cyteir Therapeutics Announces the Appointment of Dr. Jeffrey S. Humphrey to Board of Directors - Business Wire - December 17th, 2021
- BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin's Fast Onset Mechanism of Action in the Prevention of... - December 17th, 2021
- CAR T-Cell Therapy for Large B-Cell Lymphoma Who, When, and How? | NEJM - nejm.org - December 15th, 2021
- Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine... - December 15th, 2021
- AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapies for Certain Brain Disorders -... - December 15th, 2021
- Bioengineered skin breakthrough to revolutionise burns treatment - Medicine, Nursing and Health Sciences - Monash University - December 15th, 2021
- In Patients With Acute GVHD, First-Line Itolizumab Associated With High Rates of Clinical Response, Tolerability - Targeted Oncology - December 15th, 2021
- BrainStorm Cell Therapeutics Announces peer reviewed publication of NurOwn's Phase 3 Study for ALS in Muscle and Nerve - BioSpace - December 15th, 2021
- Flawed genetic switches could be at the origin of malformations or developmental diseases - News-Medical.net - December 15th, 2021
- BrainStorm Cell Therapeutics and Catalent Announce Completion of Technology Transfer for NurOwn Manufacturing - BioSpace - December 9th, 2021
- Syrian refugee is thriving five years after last-gasp gene therapy - STAT - STAT - December 9th, 2021
- What happened to Dolly the sheep? How long the first cloned adult mammal lived, and her legacy explained - iNews - December 9th, 2021
- It is imperative to reduce the cost of cancer treatment: Ramesh Ramadurai, MD, 3M India - ETHealthworld.com - December 9th, 2021
- For the 2nd time listed as the World's Top 2% scientists by Stanford University - Malaysiakini - December 9th, 2021
- Research offers a phylogenetic and ontogenetic overview of the primitive streak - News-Medical.net - December 7th, 2021
- New discoveries make steps toward lipoedema diagnosis and treatment - Mirage News - December 7th, 2021
- With its Parkinsons treatment, TreeFrog Therapeutics shows cell therapy is no longer science fiction - The Times Hub - December 7th, 2021
- The lung game: is hyperbaric oxygen therapy any good? - Financial Times - December 7th, 2021
- Irving Weissman Laboratory | Institute for Stem Cell ... - December 4th, 2021
- Nine Things To Know About Stem Cell Treatments - A Closer ... - December 4th, 2021
- Regenerative Medicine & Stem Cell Therapy Las Vegas ... - December 4th, 2021
- World AIDS Day: is a cure for HIV finally in sight? - Thomson Reuters Foundation - December 4th, 2021
- New genetic technology for gene expression analysis of cancer cells - News-Medical.net - December 4th, 2021
- Stem Cell Therapy Restores Insulin Production in Patients with Type 1 Diabetes - MD Magazine - December 4th, 2021
- It takes guts to make a heart - EurekAlert - December 4th, 2021
- Appia Bio Announces Appointment of Irving Weissman, MD, and Mark Exley, PhD, to Scientific Advisory Board - BioSpace - December 4th, 2021
- The Intramural Research Program at the Abu Dhabi Stem Cell Center (ADSCC) Signs a Letter of Intent to Collaborate with the Division of Intramural... - December 4th, 2021